HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 01, January 2018 – Weighing the options       » Scientists close in on origin of SARS       » Chinese researchers map key protein in DNA repair with near-atomic resolution       » Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients       » United States cancer drug costs increasing despite competition       » Eating yogurt may help reduce chronic inflammation in women      
INSIDE INDUSTRY For e-subscribers (PDF)
Vol 22, No 01, January 2018
Drug development companies in APAC need to raise their game to capitalise on the $33bn+ immuno-oncology treatment opportunity

Japan is currently leading the APAC region's PD-(L)1 combination development, but China is on course to outperform Japan in the near future.

Singapore's pharmaceutical market value to reach $1.15 billion by 2021

Singapore's healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research facilities. However, the market is still small due to the small population, says GlobalData.

Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients

Ryzodeg significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan, by 62%

FDA approves Amgen's Repatha (evolocumab) to prevent heart attack and stroke

Following FDA priority review, Repatha is the only PCSK9 inhibitor approved to reduce risk of heart attack, stroke and coronary revascularization

FDA approves first drug for rare disease, eosinophilic granulomatosis with polyangiitis

Formerly known as the Churg-Strauss Syndrome, it is an autoimmune disease that causes inflammation in the walls of blood vessels

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers

FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss

Luxturna is the first gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene.

Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer

This collaboration creates the world's first clinically reliable and robust patient-specific diagnostic and predictive platform to improve treatment of liver cancer. The platform will provide high throughput genomics and drug screening data from a patient's liver cancer sample, to inform timely clinical management.

Globavir announces partnership with Singhealth Duke-NUS Academic Medical Centre to study dengue treatment

Newly established Viral Research and Experimental Medicine Centre (ViREMiCS) will conduct research for the treatment of dengue and chikungunya.

Mundipharma secures exclusive license for the development and commercialisation of PAION's remimazolam in Japan

Mundipharma has entered into an exclusive license agreement with Frankfurt-listed pharmaceuticals company, PAION AG, for the development and commercialisation of its lead medicine candidate, remimazolam, in Japan.

NEWS CRUNCH  
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Addressing the ageing population / Clinical trials
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy